CStone Pharmaceuticals, a leading biopharmaceutical company focused on the discovery, development, and commercialization of innovative immuno-oncology therapies and precision medicine, and Jiangsu Hengrui Pharmaceuticals today announced a strategic partnership and exclusive license agreement for the anti-CTLA-4 mAb CS1002 in ...